Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ionis Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $50.59. Ionis Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 144.3 Mil. Therefore, Ionis Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $7,302.2 Mil.
Ionis Pharmaceuticals's quarterly market cap
increased
from Jun. 2023 ($5,874.1 Mil) to Sep. 2023 ($6,504.3 Mil) and
increased
from Sep. 2023 ($6,504.3 Mil) to Dec. 2023 ($7,302.2 Mil).
Ionis Pharmaceuticals's annual market cap
increased
from Dec. 2021 ($4,297.0 Mil) to Dec. 2022 ($5,365.5 Mil) and
increased
from Dec. 2022 ($5,365.5 Mil) to Dec. 2023 ($7,302.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ionis Pharmaceuticals's Enterprise Value for Today is $5,220.6 Mil.
Ionis Pharmaceuticals Market Cap Historical Data
The historical data trend for Ionis Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ionis Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Market Cap Distribution
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Market Cap falls into.
Ionis Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ionis Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (NAS:IONS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ionis Pharmaceuticals Market Cap Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 